Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.ufba.br/handle/ri/13435
metadata.dc.type: | Artigo de Periódico |
Título : | Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study |
Otros títulos : | Journal of Hepatology |
Autor : | Poynard, Thierry Bruix, Jordi Schiff, Eugene R. Diago, Moises Berg, Thomas Moreno Otero, Ricardo Lyra, André Castro Carrilho, Flair Griffel, Louis H. Boparai, Navdeep Jiang, Ruiyun Burroughs, Margaret Brass, Clifford A. Albrecht, Janice K. |
metadata.dc.creator: | Poynard, Thierry Bruix, Jordi Schiff, Eugene R. Diago, Moises Berg, Thomas Moreno Otero, Ricardo Lyra, André Castro Carrilho, Flair Griffel, Louis H. Boparai, Navdeep Jiang, Ruiyun Burroughs, Margaret Brass, Clifford A. Albrecht, Janice K. |
Resumen : | Background & Aims: Therapeutic options for patients failing hepatitis C retreatment are limited. EPIC3 included a prospective trial assessing long-term peginterferon alfa-2b (PegIFNa-2b) maintenance therapy in patients with METAVIR fibrosis scores (MFS) of F2 or F3 who previously failed hepatitis C retreatment. Methods: Patients with F2/F3 MFS who failed retreatment were randomized to PegIFNa-2b (0.5 lg/kg/week, n = 270) or observation (n = 270) for 36 months. Blinded liver biopsies obtained before retreatment and after maintenance therapy were evaluated using MFS and activity scores, and confirmatory testing was performed using FibroTest and ActiTest. Results: In total, 348 patients had paired biopsies: 192 patients had missing post-treatment biopsies and were considered as having no change in fibrosis/activity scores. In total, 16% of patients receiving PegIFNa-2b and 11% of observation patients had improvement in MFS (p = 0.32). More PegIFNa-2b than observation patients had improvement in activity score (20% vs. 9%; p <0.001). Among patients treated for >2.5 years, improvement in MFS or activity score was more common with PegIFNa-2b than observation (21% vs. 14%, p = 0.08 and 26% vs. 10%, p <0.001). FibroTest and ActiTest evaluations indicated significant benefit associated with PegIFNa-2b in terms of reduced fibrosis progression and improved activity score. The safety profile of PegIFNa-2b was similar to previous studies. Conclusions: PegIFNa-2b did not significantly improve MFS estimated by biopsy compared with observation; however, activity scores were significantly improved and MFS trended toward increased improvement with treatment durations >2.5 years. Both FibroTest and ActiTest were significantly improved during maintenance therapy |
Palabras clave : | Fibrosis Biomarkers Hepatitis C Liver FibroTest |
Editorial : | Journal of Hepatology |
metadata.dc.rights: | Acesso Aberto |
URI : | http://repositorio.ufba.br/ri/handle/ri/13435 |
Fecha de publicación : | 2013 |
Aparece en las colecciones: | Artigo Publicado em Periódico (Faculdade de Medicina) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
8888888888888888.pdf | 958,82 kB | Adobe PDF | Visualizar/Abrir |
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.